Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy
Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy
复制标题
DOI：
10.1111/j.1398-9995.2007.01543.x
复制
发表时间：
2007-11-01
期刊：
影响因子：
12.4
通讯作者：
Niggemann, B.
中科院分区：
文献类型：
--
作者：
Grueber, C.;Wendt, M.;Niggemann, B.
背景：一些研究表明，在食物中补充乳酸杆菌可以预防或改善儿童特应性皮炎。本研究旨在探讨鼠李糖乳杆菌GG（LGG）作为一种食品补充剂对患有特应性皮炎的婴儿的治疗效果。3-12个月的婴儿患有轻度至中度特应性皮炎（特应性皮炎的严重程度评分或SCORAD指数为15-40），随机接受LGG治疗（5 x 10（9）菌落形成单位b.i.d.）或安慰剂作为食物补充剂12周。特应性皮炎指数的严重程度评分和1%氢化可的松软膏作为补救药物的使用在治疗4、8和12周时记录（每次应用2分），并合并为症状负荷（SL）。54个婴儿（LGG组，平均+/- SD SCORAD指数24.6 +/- 8.8）和48名婴儿（安慰剂组，SCORAD指数23.6 +/-7.8）被随机化并完成治疗期（意向治疗分析）。在第4周（LGG vs安慰剂，23.8 +/- 12.4 vs 20.6 +/- 9.9）、第8周（22.5 +/- 14.6 vs 17.9 +/- 13.1）和第12周（19.6 +/- 15.4 vs 15.1 +/- 12.1），症状负荷通常随时间推移而改善，无统计学显著性组间差异。当按年龄、湿疹严重程度或急救药物的使用进行分层时，在改善方面没有发现统计学显著的组间差异，在急救药物的使用方面也没有发现显著的组间差异（0.8 +/- 45.0 g vs 3.5 +/- 29.8 g），血清总IgE平均对数增加（0.17 +/- 0.30 kU/l vs 0.26 +/- 0.45 kU/l），以及对鸡蛋或牛奶的新过敏性致敏结论：本安慰剂对照试验显示LGG对婴儿期轻中度特应性皮炎无治疗作用。
Background: Some studies have suggested that supplementation of food with lactobacilli may prevent or improve atopic dermatitis in children. This study was designed to investigate the therapeutic effect of Lactobacillus rhamnosus GG (LGG) as a food supplement in infants suffering from atopic dermatitis.Methods: Infants aged 3-12 months suffering from mild-to-moderate atopic dermatitis (severity scoring of atopic dermatitis or SCORAD index of 15-40) without current antiinflammatory treatment were randomized to receive LGG (5 x 10(9) colony forming units b.i.d.) or placebo as a food supplement for 12 weeks. Severity scoring of atopic dermatitis index and use of hydrocortisone 1% ointment as rescue medication (2 points per application) were recorded at 4, 8, and 12 weeks of treatment and combined as symptom load (SL).Results: Fifty-four infants (LGG group, mean +/- SD SCORAD index 24.6 +/- 8.8) and 48 infants (placebo group, SCORAD index 23.6 +/- 7.8) were randomized and completed the treatment period (intention-to-treat analysis). Symptom load generally improved over time at 4 weeks (LGG vs placebo, 23.8 +/- 12.4 vs 20.6 +/- 9.9), 8 weeks (22.5 +/- 14.6 vs 17.9 +/- 13.1), and 12 weeks (19.6 +/- 15.4 vs 15.1 +/- 12.1), without statistically significant group differences. When stratified for age, eczema severity or use of rescue medication, no statistically significant group differences, in improvement, were found. No significant group differences were found for the use of rescue medication (0.8 +/- 45.0 g vs 3.5 +/- 29.8 g), increase in mean logarithmic total serum IgE (0.17 +/- 0.30 kU/l vs 0.26 +/- 0.45 kU/l), and newly developed allergic sensitization against hen's egg or cow's milk (18.8% vs 10.0%).Conclusion: This placebo-controlled trial showed no therapeutic effect of LGG against mild-to-moderate atopic dermatitis in infancy.